Cargando…

Role of immune-checkpoint inhibitors in lung cancer

Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Prantesh, Jain, Chhavi, Velcheti, Vamsidhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937156/ https://www.ncbi.nlm.nih.gov/pubmed/29385894 http://dx.doi.org/10.1177/1753465817750075

Ejemplares similares

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
por: Alilou, Mehdi, et al.
Publicado: (2022)

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
por: Sehgal, Sameep, et al.
Publicado: (2016)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017)

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors
por: Wang, Xiangxue, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
por: Basudan, Ahmed M.
Publicado: (2022)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
por: Jain, P., et al.
Publicado: (2021)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020)

Research progress in immune checkpoint inhibitors for lung cancer in China
por: Gan, Jiadi, et al.
Publicado: (2021)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
por: Guha, Avirup, et al.
Publicado: (2021)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
por: Duchemann, Boris, et al.
Publicado: (2020)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
por: Punekar, Salman R., et al.
Publicado: (2022)

The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Prostate Cancer
por: Venkatachalam, Shobi, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?
por: Pozza, Daniel Humberto, et al.
Publicado: (2020)

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance
por: Weng, Chao-Yuan, et al.
Publicado: (2021)

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
por: Chhaya, Saachi, et al.
Publicado: (2023)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
por: Cadranel, Jacques, et al.
Publicado: (2019)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcjrgeqqf4erdimovd82ncnd1b